Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Covington
Colorcon
Healthtrust
US Department of Justice
McKinsey
Cerilliant
Baxter

Generated: September 18, 2018

DrugPatentWatch Database Preview

ABELCET Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Abelcet patents expire, and what generic alternatives are available?

Abelcet is a drug marketed by Leadiant Biosci Inc and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ABELCET is amphotericin b. There are fifteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphotericin b profile page.

Drug patent expirations by year for ABELCET
Pharmacology for ABELCET
Medical Subject Heading (MeSH) Categories for ABELCET
Synonyms for ABELCET
(1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyc
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriac
(1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-
(1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-
(1S,3R,4E,6E,8E,10E,12E,14E,16E,18S,19R,20R,21S,25R,27R,30R,31R,33S,35R,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo
1397-89-3
14,39-Dioxabicyclo(33.3.1)nonatriaconta-19,21,23,25,2 7,29,31-heptaene-36-carboxylic acid, 33-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-(1R-(1R*,3S*,5R*,6R*,9R*,
1407-52-9
23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,12,14,16-heptaene-38-carboxylic acid
30782-62-8
397A893
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
7XU7A7DROE
8055-20-7
AB00513832
AB00513832_02
Abelecet
ABLC
AC1NQXTD
AI3-26528
AKOS024464746
Ambap1397-89-3
Ambisome
AmBisome (TN)
Amfotericina B
Amfotericina B [INN-Spanish]
Amp B
AMPH-B
Ampho-Moronal
Amphocin
Amphomoronal
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
amphotericin b
Amphotericin B (JP17/USP/INN)
Amphotericin B [USP:INN:JAN]
Amphotericin B and cinnamon oil
Amphotericin B from Streptomyces sp.
Amphotericin B from Streptomyces sp., ~80% (HPLC), powder
Amphotericin B from Streptomyces sp., BioReagent, suitable for cell culture, ~80% (HPLC)
Amphotericin B from Streptomyces sp., Vetec(TM) reagent grade, BioReagent, suitable for cell culture, ~80%
Amphotericin B liposome
Amphotericin B solubilized, powder, gamma-irradiated, BioXtra, suitable for cell culture
Amphotericin B solution, 250 mug/mL in deionized water, sterile-filtered, BioReagent, suitable for cell culture
Amphotericin B, Streptomyces nodosus
Amphotericin-B
Amphotericine B
Amphotericine B [INN-French]
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphozone
AN-11155
Anfotericine B
APKFDSVGJQXUKY-INPOYWNPSA-N
Apothecon
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C-AmB
C06573
CAS-1397-89-3
CCG-220410
CCRIS 5963
CHEBI:2682
CS-2169
D00203
DB00681
DSSTox_CID_2601
DSSTox_GSID_22601
DSSTox_RID_76653
DTXSID9022601
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
Halizon
HMS2096A22
HSDB 3008
HSDB 3008 IAB
HY-B0221
IAB
J10140
Liposomal Amphotericin B
LMPK06000002
LS-187721
MFCD00877763
MolPort-006-113-274
Mysteclin-F
NCGC00090808-01
NCGC00260033-01
NKTR-024
NS 718
NSC 527017
Prestwick3_000410
s1636
SCHEMBL17973
SinuNase
Tox21_111027
Tox21_202484
UNII-7XU7A7DROE
ZINC253387843

US Patents and Regulatory Information for ABELCET

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leadiant Biosci Inc ABELCET amphotericin b INJECTABLE, LIPID COMPLEX;INJECTION 050724-001 Nov 20, 1995 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ABELCET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,963,297 Spontaneous vesticulation of multilamellar liposomes ➤ Try a Free Trial
5,948,441 Method for size separation of particles ➤ Try a Free Trial
5,616,334 Low toxicity drug-lipid systems ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Covington
Colorcon
Healthtrust
US Department of Justice
McKinsey
Cerilliant
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.